Kodak Establishes Pharmaceutical Unit To Tackle Shortages
US Development Bank Signs $765m Loan For Kodak
Executive Summary
Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.
You may also be interested in...
Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
AAM Welcomes Biden Moves To Strengthen Supply Chain
US president Joe Biden’s latest executive order directing a review of the API supply chain has been welcomed by the country’s off-patent industry.
Can 'Buy American’ Executive Order Shake Up ‘Dickensian’ Manufacturing Dynamics?
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.